SHANGHAI, CHINA, September 1, 2022 – WuXi STA, a subsidiary of WuXi AppTec, and Insilico Medicine, a global clinical-stage artificial intelligence-driven drug discovery and development company, today announced a strategic partnership for the integrated CMC services.
Insilico Medicine owned more than 30 pipelines under development, covering various diseases, including cancers, fibrosis, immunity, central nervous system diseases, and aging-associated diseases. Insilico’s leading anti-fibrosis drug candidate, ISM001-055, is undergoing phase 1 clinical trials in both New Zealand and China. The collaboration between WuXi STA and Insilico started in 2021, while WuXi STA provided the end-to-end CMC service, including both API and formulation development and manufacturing for ISM001-055.
As the leading CRDMO, WuXi STA has supported 35 new drugs approved globally since 2017, and the products manufactured have been launched in 105 countries. This strategic partnership is to broaden the collaboration between WuXi STA and Insilico beyond ISM001-055. Under this agreement, WuXi STA will be the preferred contract research, development, and manufacturing organization (CRDMO) partner and will provide integrated end-to-end CMC solutions to Insilico’s current and future drug discovery and development projects. The services include but are not limited to API and drug product research, development, manufacturing, and regulatory CMC dossier preparation services.
Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine, commented: “We are excited to have WuXi STA’s end-to-end CMC platform supporting our projects. The past collaboration was fruitful, and I believe this collaboration expansion will greatly accelerate our pipelines to the market and fulfill the patients’ demand around the world.”
Dr. Minzhang Chen, co-CEO of WuXi AppTec and CEO of WuXi STA, commented: “We are pleased to enhance our partnership with Insilico. We will continue building our integrated CRDMO platform and look forward to empowering more breakthroughs to benefit patients worldwide.”
About WuXi STA
WuXi STA (stapharma.com), a subsidiary of WuXi AppTec (wuxiapptec.com), is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated chemical, manufacturing and controls (CMC) from preclinical to commercial uses, including the development and manufacturing of small molecule, oligonucleotide, peptide and various complex chemical conjugate.
For more information, please visit: https://sta.wuxiapptec.com/
About Insilico Medicine
Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases.
For more information, visit www.insilico.com
